WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 17, 1168-1179. Review Article ISSN 2277–7105

ADVANCES IN ALZHEIMER'S DISEASE: A COMPREHENSIVE REVIEW OF PATHOGENESIS, DIAGNOSIS, AND TREATMENT INNOVATIONS

Ronak Gandhi*

Senior Scientist 2200 Pennsylvania Avenue NW #300e, Washington, DC 20037 Washington DC USA.

Article Received on
20 July 2024,

Revised on 10 August 2024,
Accepted on 30 August 2024

DOI: 10.20959/wjpr202417-33807

***Corresponding Author**
Ronak Gandhi
Senior Scientist 2200 Pennsylvania Avenue NW #300e, Washington, DC 20037 Washington DC USA.

ABSTRACT

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairment. It is the most common cause of dementia globally, imposing significant burdens on individuals, families, and healthcare systems. This review provides a detailed overview of the epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, current treatments, and future directions in Alzheimer's disease research and management. Recent advancements in biomarkers, genetic research, and therapeutic strategies are also explored, highlighting the complexity and ongoing challenges in combating this devastating disease.

INTRODUCTION

Alzheimer's disease (AD), first described by Alois Alzheimer in 1906, is a chronic neurodegenerative disorder primarily affecting older adults. It is characterized by progressive cognitive decline, leading to significant impairment in daily functioning and eventual death. The rising prevalence of AD, driven by increasing life expectancy, makes it one of the most pressing public health challenges of the 21st century. Currently, more than 50 million people worldwide live with dementia, with AD accounting for 60-70% of these cases.[1,2] By 2050, this number is expected to triple, underscoring the urgent need for effective prevention, diagnosis, and treatment strategies.[3]

This review provides an in-depth examination of the multifaceted aspects of AD, focusing on recent advancements in understanding its epidemiology, pathophysiology, clinical manifestations, diagnostic methods, and therapeutic options.

Epidemiology

Alzheimer's disease primarily affects older adults, with the incidence increasing exponentially after age 65.[4] In the United States alone, approximately 5.8 million people were living with AD in 2020, a figure projected to rise to 13.8 million by 2050.[1] Women are disproportionately affected, representing nearly two-thirds of AD cases.[5] This gender disparity may be attributed to women's longer life expectancy and biological factors such as estrogen's influence on brain health.[6]

Several risk factors for AD have been identified: Age is the most significant risk factor, with incidence rates doubling every five years after age 65.[4] Genetics also play a crucial role; early-onset AD is often familial, caused by mutations in the APP, PSEN1, and PSEN2 genes, while the APOE ε4 allele significantly increases the risk for late-onset AD.[7,8] Lifestyle and environmental factors, including physical inactivity, poor diet, smoking, and excessive alcohol consumption, are modifiable risk factors contributing to AD development.[9] Cardiovascular risk factors such as hypertension, diabetes, obesity, and hypercholesterolemia are also strongly associated with an increased risk of AD.[10] Additionally, higher educational attainment and lifelong cognitive engagement are associated with a lower risk of AD, likely due to the concept of cognitive reserve—the brain's ability to adapt to damage.[11]

Understanding these risk factors is crucial for developing public health strategies aimed at reducing the incidence of AD.

Pathophysiology

The pathophysiology of AD involves several complex and interrelated mechanisms leading to neurodegeneration. The two primary pathological hallmarks of AD are extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein.[12]

The amyloid cascade hypothesis posits that the accumulation of Aβ peptides in the brain initiates a cascade of events leading to neurodegeneration. Aβ is derived from the amyloid precursor protein (APP) through the actions of beta-secretase and gamma-secretase

enzymes.[13] In AD, an imbalance between Aβ production and clearance results in the formation of insoluble plaques, which trigger inflammatory responses, oxidative stress, and synaptic dysfunction. While the presence of Aβ plaques is strongly associated with cognitive decline, their exact role in disease progression remains a topic of ongoing research.[14,15]

Tau protein, which normally stabilizes microtubules in neurons, becomes hyperphosphorylated in AD, leading to the formation of neurofibrillary tangles.[16] These tangles disrupt neuronal function by impairing axonal transport, ultimately leading to cell death. Tau pathology spreads in a predictable pattern throughout the brain, correlating more closely with cognitive decline than Aβ plaques, suggesting that tau plays a central role in AD's neurodegenerative process.[17]

Chronic neuroinflammation, driven by the activation of microglia and astrocytes, is increasingly recognized as a critical component of AD pathology. These immune cells release pro-inflammatory cytokines and reactive oxygen species, exacerbating neuronal damage and promoting tau pathology. Targeting neuroinflammation represents a promising therapeutic approach in AD.[18]

The degeneration of cholinergic neurons in the basal forebrain, particularly those projecting to the hippocampus and cortex, is a hallmark of AD and correlates with cognitive deficit. This has led to the development of cholinesterase inhibitors, which aim to enhance cholinergic transmission and improve cognitive function in AD patients.[19]

In addition to APOE ε4, other genetic factors have been implicated in AD. Genome-wide association studies (GWAS) have identified numerous risk loci, including those involved in lipid metabolism, immune response, and synaptic function.[20] Understanding these genetic factors is essential for developing personalized therapeutic approaches and identifying at-risk individuals for early intervention.

Clinical manifestations

AD typically presents with insidious onset and gradual progression of cognitive and functional impairments. The clinical course can be broadly divided into three stages:

Mild Cognitive Impairment (MCI) Due to AD: Memory loss, particularly for recent events, is often the earliest and most prominent symptom. Patients may experience difficulty with complex tasks, problem-solving, and decision-making. Subtle changes in personality, social

withdrawal, and mild language difficulties may also occur.[21] While individuals with MCI have measurable cognitive deficits, these do not yet significantly impair daily functioning.[22]

Moderate AD: Memory impairment becomes more severe, with difficulty recalling important details, such as personal history and the names of close family members. Patients often become disoriented in time and place, leading to increased confusion. Language deficits worsen, with patients struggling to find the right words and understand complex sentences. Behavioral and psychological symptoms, such as agitation, aggression, wandering, and sleep disturbances, become more pronounced. Patients require assistance with activities of daily living, such as dressing, bathing, and managing finances.

Severe AD: In the final stage of AD, patients become entirely dependent on others for care. Communication is severely impaired, with patients often losing the ability to speak coherently. Physical functions deteriorate, leading to difficulty swallowing, weight loss, and increased vulnerability to infections such as pneumonia. Seizures and other neurological symptoms may occur as the disease progresses. Patients eventually become bedridden and succumb to complications of the disease.

The progression of AD can vary widely among individuals, influenced by factors such as overall health, genetics, and the presence of comorbid conditions. The duration from diagnosis to death typically ranges from 4 to 8 years, although some patients may live with the disease for 20 years or more.[23]

Diagnosis

Early and accurate diagnosis of AD is crucial for effective management and planning. The diagnostic process involves a combination of clinical evaluation, neuroimaging, and laboratory tests.

A detailed medical history and cognitive assessment are essential for diagnosing AD. Standardized cognitive tests, such as the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), are commonly used to assess cognitive function.[24] These tests evaluate memory, attention, language, visuospatial abilities, and executive function. A neurological examination helps rule out other potential causes of cognitive impairment, such as stroke, brain tumors, or infections.[25]

Magnetic Resonance Imaging (MRI) is used to detect structural changes in the brain, such as hippocampal atrophy, which is characteristic of AD. MRI can also help rule out other causes of dementia, such as vascular lesions or tumors.[26] Positron Emission Tomography (PET) imaging with amyloid or tau tracers allows for the visualization of amyloid plaques and neurofibrillary tangles in the brain. Amyloid PET imaging has been shown to improve the accuracy of AD diagnosis, particularly in cases of atypical presentations or early-stage disease.[27] While less sensitive than MRI, Computed Tomography (CT) scans are useful for excluding other causes of dementia and are often used in patients who cannot undergo MRI.[28,29]

Blood tests are conducted to rule out metabolic and infectious causes of cognitive impairment, such as vitamin deficiencies, thyroid dysfunction, or syphilis.[30] Cerebrospinal Fluid (CSF) biomarkers, including decreased Aβ42 and increased total tau and phosphorylated tau levels, are useful in diagnosing AD, particularly in the early stages of the disease. CSF analysis is commonly performed in research settings and specialized memory clinics.[31]

Recent advances have identified blood-based biomarkers that may allow for non-invasive early detection of AD. These biomarkers include plasma Aβ42/Aβ40 ratio, phosphorylated tau, and neurofilament light chain (NfL). Blood-based biomarkers offer the potential for widespread screening and monitoring of disease progression. Detailed assessments of specific cognitive domains, such as memory, attention, and language, are essential for diagnosing AD and differentiating it from other forms of dementia. Neuropsychological testing is particularly valuable in cases where cognitive deficits are subtle or atypical.[32,33]

Accurate diagnosis often requires a combination of these approaches to differentiate AD from other types of dementia and cognitive disorders.

Treatment

Currently, there is no cure for AD, and treatments focus on symptom management and slowing disease progression. Treatment strategies include pharmacological and non-pharmacological interventions.

Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, are commonly prescribed for mild to moderate AD. These drugs work by inhibiting the breakdown of

acetylcholine, a neurotransmitter involved in memory and learning. While these medications do not halt disease progression, they can improve cognitive function and delay the worsening of symptoms.[34]

Memantine, an NMDA receptor antagonist, is approved for moderate to severe AD. Memantine regulates glutamatergic activity by blocking NMDA receptors, which are involved in synaptic plasticity and memory. This drug is often used in combination with cholinesterase inhibitors to provide additional benefits.[35]

Aducanumab, a monoclonal antibody targeting Aβ plaques, was recently approved by the FDA as the first disease-modifying therapy for AD.[36] Aducanumab works by promoting the clearance of Aβ plaques from the brain, potentially slowing disease progression. However, the approval of aducanumab has been controversial due to mixed results in clinical trials and concerns about its efficacy and safety. Leqembi (lecanemab-irmb) is a disease-modifying immunotherapy approved by the FDA in July 2023 for the treatment of adults with early-stage Alzheimer's disease and mild cognitive impairment. The therapy targets amyloid-beta plaques in the brain, a hallmark of Alzheimer's disease, and has demonstrated efficacy in slowing cognitive decline in clinical trials. This approval marks a significant advancement in therapeutic options for patients in the early stages of Alzheimer's disease.[37] Kisunla™ (donanemab-azbt) got approved by the FDA in June 2024 for the treatment of Alzheimer's disease in adults with mild cognitive impairment or mild dementia. The drug demonstrated significant efficacy in slowing clinical decline in a large-scale clinical trial. Kisunla™ is administered as an intravenous infusion every four weeks. However, it carries risks, including amyloid-related imaging abnormalities (ARIA), and the prescribing information includes a boxed warning for these potential side effects.[38] Other disease-modifying therapies are in development, targeting various aspects of AD pathology, including beta-secretase inhibitors, tau aggregation inhibitors, and immunotherapies.[39]

Non-pharmacological interventions are also important in managing AD. Cognitive rehabilitation involves structured activities designed to improve or maintain cognitive function in patients with AD. Techniques include memory training, problem-solving exercises, and strategies for compensating for cognitive deficits. Cognitive rehabilitation can be tailored to individual needs and is often combined with pharmacological treatments.[40]

Regular physical activity has been shown to improve cognitive performance and overall health in individuals with AD. Exercise may enhance neuroplasticity, reduce neuroinflammation, and improve cardiovascular health, all of which contribute to better cognitive outcomes. Aerobic exercise, strength training, and balance exercises are commonly recommended.[41]

Diets rich in antioxidants, omega-3 fatty acids, and other nutrients have been associated with a reduced risk of cognitive decline. The Mediterranean diet, which emphasizes fruits, vegetables, whole grains, fish, and olive oil, has been linked to better cognitive function and a lower risk of AD.[42] Nutritional interventions, such as the use of dietary supplements, are also being explored as potential therapeutic strategies.

Maintaining social connections and engaging in mentally stimulating activities can support mental health and cognitive function in individuals with AD. Social interaction helps reduce stress, improve mood, and provide a sense of purpose, all of which are beneficial for cognitive health. Community programs, support groups, and activities that promote social engagement are encouraged.[43]

Behavioral and psychological symptoms, such as agitation, aggression, depression, and anxiety, are common in AD and can be challenging to manage. Non-pharmacological approaches, including environmental modifications and caregiver support, are often the first line of treatment. When behavioral symptoms are severe and unresponsive to non-pharmacological interventions, pharmacotherapy may be necessary. Antipsychotics, antidepressants, and anxiolytics are used cautiously due to potential side effects and the risk of worsening cognitive decline.[44]

Future directions

Advancements in understanding AD pathogenesis are guiding the development of novel therapeutic strategies. Research is increasingly focusing on early intervention and prevention, with the goal of delaying or preventing the onset of AD in at-risk individuals.

A key area of research is the development of disease-modifying therapies that target the underlying mechanisms of AD. Beta-secretase inhibitors, which reduce Aβ production, and tau aggregation inhibitors, which prevent the formation of neurofibrillary tangles, are currently being investigated in clinical trials.[45] Immunotherapies, including active and

passive vaccines, aim to enhance the immune system's ability to clear amyloid and tau from the brain.[46]

Gene therapy is an emerging field that holds promise for treating AD by modifying the expression of genes involved in the disease process. Techniques such as CRISPR/Cas9 and antisense oligonucleotides are being explored to target specific genes associated with AD risk, such as APOE ε4. Gene therapy has the potential to prevent or reverse the pathological changes in AD, although significant challenges remain.[47-49]

Stem cell therapy offers the potential to regenerate damaged neural tissue and restore cognitive function in individuals with AD.[50] Research is ongoing to develop stem cell-based treatments that can replace lost neurons, promote neurogenesis, and repair synaptic connections. While still in the experimental stages, stem cell therapy represents a promising avenue for future treatment.

Preventive strategies focused on modifiable risk factors, such as diet, exercise, and cognitive engagement, are increasingly recognized as critical in the fight against AD. Public health initiatives aimed at reducing the prevalence of cardiovascular risk factors and promoting healthy aging are expected to have a significant impact on the incidence of AD. Lifestyle interventions, including dietary changes, physical activity, and cognitive training, are being tested in large-scale clinical trials to determine their effectiveness in preventing AD.

Advances in genetic research and biomarker discovery are paving the way for personalized medicine in AD. Tailoring treatments based on an individual's genetic profile, biomarker status, and disease stage holds the potential to improve outcomes and reduce the risk of adverse effects. Personalized approaches are expected to play a key role in the future management of AD.[48]

CONCLUSION

Alzheimer's disease remains a significant challenge due to its complex pathology and lack of curative treatments. A comprehensive understanding of its epidemiology, pathophysiological mechanisms, and clinical presentations is vital for early diagnosis and effective management. Advances in research hold promise for developing innovative therapies aimed at modifying disease progression and improving the quality of life for patients and caregivers.

Collaborative efforts across scientific, medical, and societal domains are necessary to address the growing impact of AD globally.

REFERENCES

1. *2023 Alzheimer's disease facts and figures.* Alzheimers Dement, 2023; 19(4): 1598-1695.
2. Jack, C.R., Jr., et al., *NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.* Alzheimers Dement, 2018; 14(4): 535-562.
3. *Alzheimer's disease - PubMed.* Lancet (London, England), 04/24/2021. 397(10284).
4. Sperling, R.A., et al., *Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.* Alzheimers Dement, 2011; 7(3): 280-92.
5. Livingston, G., et al., *Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.* Lancet, 2020; 396(10248): 413-446.
6. Winblad, B., et al., *Defeating Alzheimer's disease and other dementias: a priority for European science and society.* Lancet Neurol, 2016; 15(5): 455-532.
7. Desikan, R.S., et al., *Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus.* Mol Psychiatry, 2015; 20(12): 1588-95.
8. Selkoe, D.J., *Alzheimer's disease: genes, proteins, and therapy.* Physiol Rev, 2001; 81(2): 741-66.
9. Reitz, C. and R. Mayeux, *Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.* Biochem Pharmacol, 2014; 88(4): 640-51.
10. Barnes, D.E. and K. Yaffe, *The projected effect of risk factor reduction on Alzheimer's disease prevalence.* Lancet Neurol, 2011; 10(9): 819-28.
11. Stern, Y., *Cognitive reserve in ageing and Alzheimer's disease.* Lancet neurology, 2012; 11: 11(11).
12. Jack, C.R., Jr., et al., *Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.* Lancet Neurol, 2013; 12(2): 207-16.
13. Hardy, J.A. and G.A. Higgins, *Alzheimer's disease: the amyloid cascade hypothesis.* Science, 1992; 256(5054): 184-5.
14. Sperling, R.A., et al., *The impact of amyloid-beta and tau on prospective cognitive decline in older individuals.* Ann Neurol, 2019; 85(2): 181-193.

15. Rolyan, H., et al., *Amyloid-beta protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease.* J Neural Transm (Vienna), 2011; 118(5): 699-712.
16. Mattsson, N., et al., *Plasma tau in Alzheimer disease.* Neurology, 2016; 10, 10: 87(17).
17. Harrison, T.M., et al., *Tau deposition is associated with functional isolation of the hippocampus in aging.* Nature Communications, 2019; 10, 1: 2019-10-25. 10(1).
18. Heneka, M.T., et al., *Neuroinflammation in Alzheimer's disease.* Lancet Neurol, 2015; 14(4): 388-405.
19. Chen, Z.-R., et al., *Role of Cholinergic Signaling in Alzheimer's Disease.* Molecules, 2022; 03: 27(6).
20. Andrade-Guerrero, J., et al., *Alzheimer's Disease: An Updated Overview of Its Genetics.* International Journal of Molecular Sciences, 2023; 02: 24(4).
21. Petersen, R.C., et al., *Mild cognitive impairment: clinical characterization and outcome.* Arch Neurol, 1999; 56(3): 303-8.
22. Morris, J.C., *Mild cognitive impairment and preclinical Alzheimer's disease.* Geriatrics, 2005; 9-14.
23. Monfared, A.A.T., et al., *Alzheimer's Disease: Epidemiology and Clinical Progression.* Neurology and Therapy, 2022; 06: 11(2).
24. McKhann, G.M., et al., *The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.* Alzheimers Dement, 2011; 7(3): 263-9.
25. Wei, Y.-C., et al., *Normative Data of Mini-Mental State Examination, Montreal Cognitive Assessment, and Alzheimer's Disease Assessment Scale-Cognitive Subscale of Community-Dwelling Older Adults in Taiwan.* Dementia and Geriatric Cognitive Disorders, 2022; 51(4).
26. Živanović, M., et al., *The role of magnetic resonance imaging in the diagnosis and prognosis of dementia.* Biomolecules and Biomedicine, 2023; 04: 04, 23(2).
27. Chapleau, M., et al., *The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.* Journal of Nuclear Medicine, 2022; 06: 63(1).
28. Tiwari, S., et al., *Alzheimer's disease: pathogenesis, diagnostics, and therapeutics.* International Journal of Nanomedicine, 2019; 14.
29. Johnson, K.A., et al., *Brain Imaging in Alzheimer Disease.* Cold Spring Harbor Perspectives in Medicine, 2012; 04: 2(4).

30. *Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic - PubMed.* Nature reviews. Neurology, 2018; 14(11).
31. Papaliagkas, V., et al., *CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease.* Int J Mol Sci, 2023; 24(10).
32. Hashimoto, K., *Biomarkers for Alzheimer's disease: from pathogenesis to drug development.* Eur Arch Psychiatry Clin Neurosci, 2018; 268(5): 441-442.
33. Cummings, J., *The Role of Biomarkers in Alzheimer's Disease Drug Development.* Adv Exp Med Biol, 2019; 1118: 29-61.
34. Cummings, J.L., T. Morstorf, and K. Zhong, *Alzheimer's disease drug-development pipeline: few candidates, frequent failures.* Alzheimers Res Ther, 2014; 6(4): 37.
35. Liu, J., et al., *The Role of NMDA Receptors in Alzheimer's Disease.* Frontiers in Neuroscience, 2019; 13.
36. Sevigny, J., et al., *The antibody aducanumab reduces Abeta plaques in Alzheimer's disease.* Nature, 2016; 537(7618): 50-6.
37. Huang, L.-K., et al., *Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update.* Journal of Biomedical Science, 2023; 30(1).
38. *FDA approves treatment for adults with Alzheimer's disease*. Available from: FDA approves treatment for adults with Alzheimer's disease.
39. Zhang, J., et al., *Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.* Signal Transduction and Targeted Therapy, 2024; 9: 1, 2024-08-23. 9(1).
40. Bahar-Fuchs, A., L. Clare, and B. Woods, *Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer's or vascular type: a review.* Alzheimer's Research & Therapy, 2013; 5(4).
41. Quigley, A., M. MacKay-Lyons, and G. Eskes, *Effects of Exercise on Cognitive Performance in Older Adults: A Narrative Review of the Evidence, Possible Biological Mechanisms, and Recommendations for Exercise Prescription.* Journal of Aging Research, 2020; 2020.
42. *What Do We Know About Diet and Prevention of Alzheimer's Disease*. Available from: https://www.nia.nih.gov/health/alzheimers-and-dementia/what-do-we-know-about-diet-and-prevention-alzheimers-disease.
43. Woods, B., et al., *Cognitive stimulation to improve cognitive functioning in people with dementia*. The Cochrane Database of Systematic Reviews, 2023; 2023(1).

44. Carrarini, C., et al., *Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions.* Frontiers in Neurology, 2021; 12.
45. Pasieka, A., et al., *Dual Inhibitors of Amyloid-β and Tau Aggregation with Amyloid-β Disaggregating Properties: Extended In Cellulo, In Silico, and Kinetic Studies of Multifunctional Anti-Alzheimer's Agents.* ACS Chemical Neuroscience, May, 2021; 12(11): 21.
46. Song, C., et al., *Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.* Translational Neurodegeneration, 2022; 11.
47. Barman, N.C., et al., *CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease—A Narrative Review.* Neurology and Therapy, 2020; 9(2): 12.
48. Pauwels, E.K.J. and G.J. Boer, *Alzheimer's Disease: A Suitable Case for Treatment with Precision Medicine?* Medical Principles and Practice, 2024; 33(4): 08-14.
49. Yu, J., T. Li, and J. Zhu, *Gene Therapy Strategies Targeting Aging-Related Diseases.* Aging and Disease, 2023; 14(2): 04-04.
50. Chen, X., et al., *Neural Stem Cells in the Treatment of Alzheimer's Disease: Current Status, Challenges, and Future Prospects.* Journal of Alzheimer's Disease, 2023; 94(1).